Why the study?
Phosphodiesterases play a pivotal role in brain development and disease, prompting an evaluation of evidence regarding PDE4B enzymes as potential therapeutic targets for indications such as schizophrenia, neuroinflammation, and cognitive function.
Key points are not available for this paper at this time.
Design
Review
PDE4B is a key regulator of brain signaling and represents a promising therapeutic target for various neurological and cognitive disorders.
Phosphodiesterases (PDEs) are the only superfamily of enzymes that have the ability to break down cyclic nucleotides and, as such, they have a pivotal role in neurological disease and brain development. PDEs have a modular structure that allows targeting of individual isoforms to discrete brain locations and it is often the location of a PDE that shapes its cellular function. Many of the eleven different families of PDEs have been associated with specific diseases. However, we evaluate the evidence, which suggests the activity from a sub-family of the PDE4 family, namely PDE4B, underpins a range of important functions in the brain that positions the PDE4B enzymes as a therapeutic target for a diverse collection of indications, such as, schizophrenia, neuroinflammation, and cognitive function.
No takes yet. Share an insight, caveat, or question.
Tibbo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: